A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain

Trial Profile

A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2018

At a glance

  • Drugs Olorinab (Primary)
  • Indications Abdominal pain
  • Focus Adverse reactions
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 09 May 2018 According to an Arena Pharmaceuticals media release, the company expects to completed enrollment in Q2 2018 and expects results in Q3 2018.
    • 14 Mar 2018 According to an Arena Pharmaceuticals media release, study is currently enrolling patients and data is expected in Q2 2018.
    • 07 Aug 2017 According to an Arena Pharmaceuticals media release, data readout from the study is expected around year-end 2017 to Q1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top